Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

Table 3

Patient demographics and serum mesothelin and MPF concentrations in MM patients and controls.

Group	Number of cases; (females)	Mean age, years; (range)	Serum mesothelin; (nM)^a,d	Serum N-ERC (MPF) (ng/mL)^a,b,d	Serum MPF; (ng/mL)^a,c,d
MM	66 (5)	66 (48–84)	4.29±0.7	0.16±0.05	40.37±6.1
Cancer lung	19 (7)	72 (58–82)	1.77±0.4^∗∗	0.23±0.1^∗∗	15.13±3.4^∗∗
Cancer other	10 (5)	73 (50–82)	0.87±0.3^∗∗∗	0.58±0.19^∗∗∗	13.07±2.3^∗∗
Asbestos exposed	18 (8)	61 (37–86)	0.41±0.1^∗∗∗	0.04±0.02^∗∗∗	9.66±1.6^∗∗∗
ARD	14 (1)	73 (60–82)	1.07±0.1^∗∗∗	0.10±0.06^∗∗∗	12.19±2.3^∗∗∗
PE-benign	23 (7)	68 (32–86)	0.70±0.2^∗∗∗	0.07±0.3^∗∗∗	9.53±1.2^∗∗∗

aexponentiated mean of log transformed data plus/minus standard error of log transformed data *100.
^bMPF concentrations determined from Human N-ERC/Mesothelin Assay (IBL).
^cMPF concentrations determined from Human MPF Assay (MBL).
^dsignificant difference between indicated cohorts and the mesothelioma cohort as a whole (𝑛=66) as determined by Student’s 𝑡-test (** is 𝑃<0.001; *** is 𝑃<0.0001).